Table 3 Comparison of patients with (painDETECT ≥13) and without neuropathic pain symptoms

Female sex, n (%)

61 (62.2)

43 (70.5)

0.288

Age (years), mean ± SD

57.7 (10.9)

56.3 (11.0)

0.432

Education, n (%)

 Low

22 (22.4)

15 (25.0)

 Medium

57 (58.2)

36 (60.0)

 High

19 (19.4)

9 (15)

0.768

Current smoking, n (%)

15 (15.3)

12 (19.7)

0.476

Current alcohol, n (%)

73 (74.5)

47 (77.0)

0.715

Disease duration (years), median (IQR)

6.0 (3.0–12.0)

6.0 (3.0–12.0)

0.912

FM, n (%)

6 (6.1)

17 (28.3)

<0.001

Prescribed RA medication, n (%)

 DMARD

58 (59.2)

37 (60.7)

0.854

 DMARD plus biologic

25 (25.5)

15 (24.6)

0.897

 Biologic

11 (11.2)

7 (11.5)

0.961

 NSAID only

3 (3.1)

2 (3.3)

1.000

Self-reported current pain medication, n (%)

37 (37.8)

44 (73.3)

<0.001

Self-reported current neuropathic pain medication, n (%)

4 (4.1)

5 (8.3)

0.263

Current pain (0–10), mean ± SD

2.5 (2.2)

4.6 (2.3)

<0.001

Strongest pain (0–10), mean ± SD

3.2 (2.6)

6.0 (2.3)

<0.001

Average pain (0–10), mean ± SD

2.7 (2.2)

4.8 (2.1)

<0.001

DAS28 (0–10), mean ± SD

2.0 (1.0)

2.3 (1.0)

0.095

ESR (mm/hour), median (IQR)

8.0 (2.5–15.0)

8.0 (5.0–17.0)

0.610

CRP (mg/l), median (IQR)

2.0 (1.0–7.0)

3.0 (2.0–8.0)

0.107

SJC (0–28), mean ± SD

0 (0–1)

0 (0–1)

0.603

TJC (0–28), mean ± SD

0 (0–1)

0 (0–2)

0.016

HAQ-DI (0–3), mean ± SD

0.5 (0.5)

1.1 (0.6)

<0.001

SF-36 PCS (0–100), mean ± SD

44.9 (8.2)

36.4 (8.7)

<0.001

SF-36 MCS (0–100), mean ± SD

52.7 (9.4)

46.5 (10.6)

<0.001